Nextech Invest Ltd. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001595430

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Q2 2026 · 15 positions · Total reported value $2.11B · Top-10 concentration 98.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 27.8% · 1 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +54.9% · vs SPY +40.1% · Prev Value $1.42B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Nextech Invest Ltd. disclosed 15 equity positions with a combined reported value of $2.11B. The filing implies a focused portfolio: its ten largest positions account for 98.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RVMD ($1.42B), PBLS ($127.63M), RLAY ($126.79M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Nextech Invest Ltd. opened 1 new positions, trimmed 1 and fully exited 3, a turnover rate of 27.8% of positions. The portfolio's overlap with the prior quarter was 78% of names.

The largest new positions opened in Q2 2026 were PBLS ($127.63M).

Of the 3 positions fully exited versus the prior quarter, the largest were TNGX ($152.01M), CGEM ($16.22M), SPRY ($4.90M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PBLS PARABILIS MEDICINES INC · $127.63M

Fully Exited (vs previous quarter)

  • TNGX TANGO THERAPEUTICS INC · prev qtr: $152.01M
  • CGEM CULLINAN THERAPEUTICS INC · prev qtr: $16.22M
  • SPRY ARS PHARMACEUTICALS INC · prev qtr: $4.90M

Insider Transactions (Form 4)

Latest Nextech Invest Ltd. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Nextech Invest Ltd. files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 15 positions worth $2.11B in total. HoldingsHub carries 6 quarters of its filings (Q1 2025–Q2 2026).

Portfolio Structure

  • 15 positions · $2.11B reported value (Q2 2026)
  • Top 10 holdings = 98.0% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 67.6%
  • Average position size: $140.49M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 added, 1 reduced, 3 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious stance with a slight bias towards growth within the healthcare sector. The addition of new positions and the increase in stakes in certain companies suggest a focus on innovative biotech and pharmaceutical companies. 2. Key Moves: - Added: Parabalis Medicines (PBLS) and Monte Rosa Therapeutics (GLUE). This indicates a willingness to explore new opportunities in the healthcare sector. - Reduced: Tyra Biosciences (TYRA) by 12.4%. This could be due to a reassessment of the company's potential or market conditions. - Increased: Relay Therapeutics (RLAY) by 22.6%, and Arvinas Inc. (ARVN) by 108.1%. This suggests confidence in the growth prospects of these companies. 3. Portfolio Structure: - Passive/Active: The fund seems to have an active management approach, as evidenced by the changes in positions and the addition of new holdings. - Sector Bias: Strong bias towards healthcare, particularly biotechnology and pharmaceuticals. - Risk Appetite: Moderate to high, given the significant increases in stakes in certain companies and the exploration of new sectors. 4. Per-Holding One-Liner: - RVMD: Revolution Medicines Inc. - Developing novel therapies for cancer. - PBLS: Parabalis Medicines Inc. - Focused on developing treatments for rare genetic disorders. - RLAY: Relay Therapeutics Inc. - Developing therapies for neurological diseases. - TYRA: Tyra Biosciences Inc. - Developing treatments for cancer. - ALMS: Alumis Inc. - Developing therapies for rare genetic disorders. - ORIC: Oric Pharmaceuticals Inc. - Focused on developing therapies for cancer. - KYMR: Kymera Therapeutics Inc. - Developing therapies for cancer. - ZYME: Zymeworks Inc. - Developing therapies for cancer and other diseases. - GLUE: Monte Rosa Therapeutics - Developing therapies for cancer. - ARVN: Arvinas Inc. - Developing therapies for cancer. 5. One-Sentence Style Summary: The Nextech Invest Ltd. fund maintained a cautious yet growth-oriented approach in Q2 2026, focusing on healthcare sector opportunities with a mix of established and emerging companies.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 7.60M $1.42B 67.55%
67.55%
Hold
2 4.66M $127.63M 6.06%
6.06%
New
3 6.78M $126.79M 6.02%
6.02%
Add
4 3.55M $113.50M 5.39%
5.39%
Reduce
5 3.54M $99.64M 4.73%
4.73%
Hold
6 7.16M $77.57M 3.68%
3.68%
Hold
7 278.90K $31.98M 1.52%
1.52%
Hold
8 1.11M $29.12M 1.38%
1.38%
Hold
9 761.15K $18.42M 0.87%
0.87%
Add
10 1.12M $17.12M 0.81%
0.81%
Add
11 4.45M $16.69M 0.79%
0.79%
Hold
12 952.40K $10.46M 0.50%
0.50%
Hold
13 450.00K $6.72M 0.32%
0.32%
Hold
14 7.42M $4.11M 0.20%
0.20%
Hold
15 2.32M $4.02M 0.19%
0.19%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 22% of its Top-10 each quarter and backtests at F1 78% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (4 quarters)

Avg precision 78% · recall 78% · F1 78% · avg rank error 1.4 · Top-10 turnover 22%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q3 80% 80% 80% RVMD · ORIC · TYRA · TNGX · KYMR · ZYME · RLAY · SPRY · CRGX · ARVN RVMD · ORIC · TYRA · TNGX · RLAY · KYMR · ZYME · ARVN · ALMS · CNTX
2025-Q4 80% 80% 80% RVMD · ORIC · TYRA · TNGX · RLAY · KYMR · ZYME · ALMS · ARVN · CNTX RVMD · TYRA · TNGX · ORIC · RLAY · ZYME · ALMS · KYMR · ENGN · MRSN
2026-Q1 80% 80% 80% RVMD · TYRA · TNGX · ORIC · RLAY · ZYME · ALMS · KYMR · ENGN · MRSN RVMD · TYRA · TNGX · ORIC · ALMS · RLAY · ZYME · KYMR · CTMX · CNTX
2026-Q2 ★ 70% 70% 70% RVMD · TNGX · TYRA · ORIC · ALMS · RLAY · ZYME · KYMR · CTMX · CNTX RVMD · PBLS · RLAY · TYRA · ALMS · ORIC · KYMR · ZYME · GLUE · ARVN

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Nextech Invest Ltd. buy in 2026-Q2?

In its 2026-Q2 13F filing, Nextech Invest Ltd. reported 15 equity positions worth $2.11B in aggregate; its largest disclosed positions were RVMD ($1.42B), PBLS ($127.63M), RLAY ($126.79M).

How large is Nextech Invest Ltd.'s portfolio?

Nextech Invest Ltd. reported $2.11B of long equity holdings across 15 positions as of 2026-Q2. Top-10 holdings account for 98.0% of reported value.

What is Nextech Invest Ltd.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/nextech-invest/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →